Drug Approval | July 14, 2023
Lupin receives approval from USFDA for Chlorpromazine Hydrochloride Tablets USP
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
The strategic acquisition demonstrates the company’s commitment to increasing OTC consumer convenience in eye care
Dolutegravir Tablets for Oral Suspension (RLD Tivicay PD®) had estimated annual sales of USD 1 million in the U.S. (IQVIA MAT March 2023)
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
PEEK brings a new quality to dental care for patients
The launch of HULIO in the United States is an important milestone for Biocon Biologics
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
This product will be manufactured at Lupin's Pithampur facility in India
The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.
Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S.
Subscribe To Our Newsletter & Stay Updated
